knowledge -WSS

knowledge

author：focus 2025-10-02 04:55:34 - browse：56245

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Why liver experts renamed NASH to MASH, and NAFLD to MASLD

WSS

Readout LOUD podcast: live from JPM 2024

Heart disease and mental health: A look at cardiac psychology

Millions may soon lose Medicaid when they don't have to

How I ended up pumping milk in a bathroom stall at JPM 2024

Health and fitness trackers are measuring the wrong things

FDA approves first new drug developed for postpartum depression

knowledge

knowledge

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

HHS names first

Apple is now the first public company to be valued at $3 trillion

Eli Lilly’s Mounjaro succeeds in second weight

Medicare details structure of new drug price negotiation program

Novo: Oral version of Ozempic leads to 15% weight loss

Walensky prepares to leave CDC — and Congress — behind

How I ended up pumping milk in a bathroom stall at JPM 2024

Continuity nursing helped my family in our darkest PICU moments

Idaho abortion case may prompt more restrictions in other states

hotspot

Reanimated hearts work just as well for transplants, study finds

Doulas covered by Medicaid under New York's new plan

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Doulas covered by Medicaid under New York's new plan

Biotech reporter’s notebook: A sunnier mood at JPM 2024

focus

knowledge

Wikipedia

Wikipedia